317 related articles for article (PubMed ID: 33959491)
21. Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma.
Ma S; Rudra S; Campian JL; Dahiya S; Dunn GP; Johanns T; Goldstein M; Kim AH; Huang J
Neurooncol Adv; 2020; 2(1):vdaa126. PubMed ID: 33235995
[TBL] [Abstract][Full Text] [Related]
22. Establish six-gene prognostic model for glioblastoma based on multi-omics data of TCGA database.
Lei CG; Jia XY; Sun WJ
Yi Chuan; 2021 Jul; 43(7):665-679. PubMed ID: 34284982
[TBL] [Abstract][Full Text] [Related]
23. RARRES2 is Downregulated in Isocitrate Dehydrogenase 1 Mutant Glioma Patients and Served as an Unfavorable Prognostic Factor of Glioma.
Wang H; Wang X; Xu L; Zhang J
World Neurosurg; 2023 Aug; 176():e610-e622. PubMed ID: 37271257
[TBL] [Abstract][Full Text] [Related]
24. Multi-omics landscape of circadian rhythm pathway alterations in Glioma.
Zhang C; Xu J; Chen L; Lin X
Bioengineered; 2021 Dec; 12(1):3294-3308. PubMed ID: 34224318
[TBL] [Abstract][Full Text] [Related]
25. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
Liang Y; Bollen AW; Aldape KD; Gupta N
BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
[TBL] [Abstract][Full Text] [Related]
26. Identification of Key Pathways and Genes in the Orai2 Mediated Classical and Mesenchymal Subtype of Glioblastoma by Bioinformatic Analyses.
Yuan F; Yi L; Hai L; Wang Y; Yang Y; Li T; Tong L; Ma H; Liu P; Ming H; Ren B; Yu S; Lin Y; Yang X
Dis Markers; 2019; 2019():7049294. PubMed ID: 31772693
[TBL] [Abstract][Full Text] [Related]
27. Identification of Periostin as a Potential Biomarker in Gliomas by Database Mining.
Faried A; Hermanto Y; Tjahjono FP; Valentino A; Arifin MZ
World Neurosurg; 2020 Mar; 135():e137-e163. PubMed ID: 31785437
[TBL] [Abstract][Full Text] [Related]
28. Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan-cancer analysis.
Liu H; Zhang B; Sun Z
Cancer Commun (Lond); 2020 Jan; 40(1):43-59. PubMed ID: 32067422
[TBL] [Abstract][Full Text] [Related]
29. A Five-lncRNAs Signature-Derived Risk Score Based on TCGA and CGGA for Glioblastoma: Potential Prospects for Treatment Evaluation and Prognostic Prediction.
Niu X; Sun J; Meng L; Fang T; Zhang T; Jiang J; Li H
Front Oncol; 2020; 10():590352. PubMed ID: 33392085
[TBL] [Abstract][Full Text] [Related]
30. Identification of an autophagy-related 10-lncRNA-mRNA signature for distinguishing glioblastoma multiforme from lower‑grade glioma and prognosis prediction.
Wei B; Wang L; Zhao J
Gen Physiol Biophys; 2021 Jul; 40(4):257-274. PubMed ID: 34350832
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Transcriptomic Analysis and Experimental Validation Identify lncRNA HOXA-AS2/miR-184/COL6A2 as the Critical ceRNA Regulation Involved in Low-Grade Glioma Recurrence.
Chen PY; Li XD; Ma WN; Li H; Li MM; Yang XY; Li SY
Onco Targets Ther; 2020; 13():4999-5016. PubMed ID: 32581558
[TBL] [Abstract][Full Text] [Related]
32. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma.
Qiu H; Tian W; He Y; Li J; He C; Li Y; Liu N; Li J
Front Oncol; 2021; 11():654350. PubMed ID: 33954112
[TBL] [Abstract][Full Text] [Related]
33. Establishment and Validation of a 5 m6A RNA Methylation Regulatory Gene Prognostic Model in Low-Grade Glioma.
Bai Z; Wang X; Zhang Z
Front Genet; 2022; 13():655169. PubMed ID: 35281815
[No Abstract] [Full Text] [Related]
34. CHI3L2 Is a Novel Prognostic Biomarker and Correlated With Immune Infiltrates in Gliomas.
Liu L; Yang Y; Duan H; He J; Sun L; Hu W; Zeng J
Front Oncol; 2021; 11():611038. PubMed ID: 33937022
[TBL] [Abstract][Full Text] [Related]
35. Expression and Prognostic Role of PANK1 in Glioma.
Zhao Z; Xu X; Ma S; Li L
Comb Chem High Throughput Screen; 2024; 27(5):715-724. PubMed ID: 37138430
[TBL] [Abstract][Full Text] [Related]
36. Chromobox 7/8 serve as independent indicators for glioblastoma
Zheng ZQ; Yuan GQ; Kang NL; Nie QQ; Zhang GG; Wang Z
Front Neurol; 2022; 13():912039. PubMed ID: 36034290
[TBL] [Abstract][Full Text] [Related]
37. A comprehensive analysis of the angiogenesis-related genes in glioblastoma multiforme vs. brain lower grade glioma.
Biterge-Sut B
Arq Neuropsiquiatr; 2020 Jan; 78(1):34-38. PubMed ID: 32074192
[TBL] [Abstract][Full Text] [Related]
38. DKK3 expression is associated with immunosuppression and poor prognosis in glioblastoma, in contrast to lower-grade gliomas.
Han MH; Baek JM; Min KW; Cheong JH; Ryu JI; Won YD; Kwon MJ; Koh SH
BMC Neurol; 2023 May; 23(1):183. PubMed ID: 37149563
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma.
Zhang Q; Liu XJ; Li Y; Ying XW; Chen L
Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865
[TBL] [Abstract][Full Text] [Related]
40. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
